SCHEMBL167917

SCHEMBL167917

O=C(O)c1cc(Cl)c(C(=O)N2CCC(F)(F)C2)cc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.41
PTGER1 P34995 2/20 0.41
MCL1 Q07820 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
HPGD P15428 4/20 0.40
DPP4 P27487 1/20 0.40
KCNH2 Q12809 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
CHRM3 P20309 2/20 0.39
CHRM4 P08173 1/20 0.39
CLCN2 P51788 1/20 0.39
CHRM2 P08172 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
MITF O75030 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169355 0.91 DPP4 (0.42) MRGPRX4HPGDDPP4KCNH2DPP7
SCHEMBL257499 0.83 LRRK2 (0.62) KCNH2
SCHEMBL256490 0.83 LRRK2 (0.58)
SCHEMBL167115 0.81 HPGD (0.54) FOLH1PTGER1MCL1HPGDALDH1A1
SCHEMBL168000 0.81 HTT (0.56) HPGDKDM4EALDH1A1MEN1NPC1
SCHEMBL257126 0.81 LRRK2 (0.39) MRGPRX4KDM4EALDH1A1NPY4R
SCHEMBL383618 0.73 FOLH1 (0.58) FOLH1PTGER1MCL1MRGPRX4HPGD
SCHEMBL18474494 0.73 ALDH1A1 (0.51) ALDH1A1NPC1RAB9ASMN1; SMN2APP
SCHEMBL10089235 0.73 FOLH1 (0.69) FOLH1PTGER1MCL1KDM4EALDH1A1
SCHEMBL167413 0.72 HPGD (0.52) HPGDALDH1A1POLBMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 FOLH1 4156/4885PTGER1 4158/4885MCL1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.